

Paraproteins in CLL Are Frequently the Product of Another Clone.

Dennis A. Carney, Srinivas R. Mummadi, Susan A. Lerner, and Michael J. Keating Blood 2004 104:1912;

Article Info & Metrics

Abstract

Paraproteins are found in 5–10% of CLL patients using conventional techniques and in a higher number using more sensitive techniques. The significance of this finding is uncertain although it has been suggested to be associated with a worse prognosis. When a paraprotein occurs with CLL it is usually considered to be a product of the leukemic clone. However there is an increased incidence of both B cell clonal expansions and monoclonal immunoglobulins (Igs) in the elderly suggesting an alternative source may exist.

We examined the clinicopathological features of 34

Previous



Advertisement

cases of paraproteins who had an immunophenotype consistent with CLL (CD5+ B cells and CD23+ if tested). These were untreated patients who had an elevation of one or more immunoglobulins (Igs) on routine screening and subsequently had immunofixation (IF) to determine the presence of a paraprotein.

In a database of chronic lymphoproliferative disorders 1380 patients had Ig quantitation and 168 were found to have an elevation in one or more lgs. Cases were excluded from this group if the disease was found to be T cell, CD5- or CD23-. This left 116 CLL patients with elevated Igs, of which 53 had IF. A polyclonal increase was detected in 19 and paraproteins in 34 (14 IgG, 16 IgM, 1 IgA and 3 oligoclonal). The level of paraprotein ranged from 0.2-4.4 g/dl for IgG, 0.2-2.4 g/dl for IgM and was 0.4 g/dl for IgA. Bence Jones Protein was associated with both IgG and IgM paraproteins when tested (2 patients in each group). Suppression of other Igs was observed in 12 patients (35%) with paraproteins and only one patient (5%) with a polyclonal increase.

When compared to patients with a polyclonal increase in Igs, the patients with paraproteins had more advanced disease and higher bone marrow lymphocytosis, β 2-microglobulin and LDH (p<0.05). The immunophenotype in approximately half of the cases in both groups was atypical for CLL with features including CD22+, CD79b+, FMC7+ and moderate to strong expression of surface Ig. Cytogenetic abnormalities were present in 8 of 34 cases with paraproteins but were not detected in the polyclonal group. The most frequent abnormality was trisomy 12 found in 4 cases. The survival of the 2 groups was not statistically different with a median



follow up of 104 months.

The origin of paraproteins is usually considered to be the CLL clone with CLL cells capable of secreting IgM as well as producing IgG and IgA paraproteins by isotype switching. In this cohort 5/14 patients with an IgG paraprotein had a different light chain expressed on the CLL clone. In addition 3/16 patients with IgM paraproteins had biclonal IgMs and in one case the 2 Igs had different light chains suggesting that at least one was not a product of the CLL clone. In conclusion, paraproteins in CLL are frequently not the product of the CLL clone but may reflect an associated agerelated restriction in B cell repertoire and existence of other clonal expansions. Further studies are needed to determine if CLL emerges from one of these clones or develops independently.

2005, The American Society of Hematology

Potential Articles of Interest

Immune response profiles after caterpillar exposure: a case report Tamar A Smith-Norowitz et al., Journal of Inflammation Research, 2010

Long-term persistence of IgE anti-influenza A HIN1 virus antibodies in serum of children and adults following influenza A vaccination with subsequent H1N1 infection: a case study Tamar A Smith-Norowitz et al., Journal of Inflammation

Research, 2012

Bovine milk derived skimmed milk powder and whey protein concentrate modulates Citrobacter rodentium shedding in the mouse intestinal tract PeerJ

Effects of Salmonella enterica serovar Enteritidis infection on egg production and the immune response of the laying duck Anas platyrhynchos PeerJ

Bone marrow mesenchymal stem cells as nuclear donors improve viability and health of cloned horses R Olivera et al., Stem Cells and Cloning: Advances and

Powered by TREND MD

Applications, 2018

G Previous

▲ Back to top

S blood

Leading the way in experimental and clinical research in hematology

Advertisement

American Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036 Phone 202-776-0544 | Fax 202-776-0545

Current Issue	About Blood	Submit to Blood	Information for:
First Edition	Subscriptions	Blood App	Authors
Collections	Newsroom	Alerts	Subscribers
All Issues	Copyright	RSS	Institutions/Librarians
Abstracts	Public Access	Contact Us	Advertising in Blood
Video Library	Permissions	Order Reprints	Terms and Conditions

Blood Journals V f

🎔 🛗 in 🖸

Advertisement	
Copyright © 2019 by American Society of Hematology	Privacy Policy Terms of Service Contact Us